Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 12, 2025 • 1:01 PM ET

Date/Time Source News Release
06/03/2025 04:49 PM EDT Business Wire ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders
06/03/2025 03:58 PM EDT PR Newswire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders
06/02/2025 06:00 AM EDT GlobeNewswire atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
05/29/2025 08:30 AM EDT GlobeNewswire atai Life Sciences to Participate in Upcoming Investor Conferences
05/20/2025 07:00 AM EDT GlobeNewswire atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
05/14/2025 07:00 AM EDT GlobeNewswire atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
05/13/2025 07:01 AM EDT GlobeNewswire atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
03/17/2025 08:00 AM EDT GlobeNewswire atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
03/11/2025 07:00 AM EDT GlobeNewswire atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
03/05/2025 07:00 AM EST GlobeNewswire atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
Page